FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1596560878> ?p ?o ?g. }

• W1596560878 abstract "Excessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases. The CXCR2 chemokine receptor is important in controlling the extravasation and activation of neutrophils. Selective antagonism of the CXCR2 receptor is a potential approach to reducing neutrophil migration and activation. Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.(1) First time in human (FTIH) double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single ascending and repeat oral doses of danirixin in healthy male subjects; (2) single-dose study of age, gender, food, and proton-pump inhibitor effects on the pharmacokinetics of danirixin in healthy adult subjects; and placebo-controlled study of the pharmacokinetics of danirixin in healthy elderly subjects.There were no serious adverse events and no adverse events considered to be of clinical relevance. There were no withdrawals due to adverse events. Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose. Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50% for 50 mg and 100 mg danirixin, and 72% at 200 mg). There was a 37% decrease in Cmax and a 16% decrease in AUC (0-∞) following administration of danirixin in the presence of food. Cmax also decreased by 65% when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days. The AUC (0-∞) and Cmax were 50% lower in elderly subjects compared with younger subjects.The dose-dependent inhibition of agonist-induced neutrophil activation following single and repeated once daily oral administration of danirixin suggests that this CXCR2 antagonist may have benefit in neutrophil-predominant inflammatory diseases. Co-administration with food, gastric acid reducing agents, and variable exposure in the elderly have important clinical implications that need to be taken into consideration in subsequent clinical evaluations.ClinicalTrials.gov identifiers: NCT01209052 and NCT01209104." @default.
• W1596560878 created "2016-06-24" @default.
• W1596560878 creator A5006853195 @default.
• W1596560878 creator A5012242776 @default.
• W1596560878 creator A5021869798 @default.
• W1596560878 creator A5037747729 @default.
• W1596560878 creator A5041661080 @default.
• W1596560878 creator A5043635819 @default.
• W1596560878 creator A5046940384 @default.
• W1596560878 creator A5081663338 @default.
• W1596560878 creator A5091287615 @default.
• W1596560878 date "2015-06-20" @default.
• W1596560878 modified "2023-10-06" @default.
• W1596560878 title "The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects" @default.
• W1596560878 cites W1491122445 @default.
• W1596560878 cites W1580622436 @default.
• W1596560878 cites W1724443945 @default.
• W1596560878 cites W1988019968 @default.
• W1596560878 cites W1992347215 @default.
• W1596560878 cites W2016754841 @default.
• W1596560878 cites W2019562019 @default.
• W1596560878 cites W2037542404 @default.
• W1596560878 cites W2069756383 @default.
• W1596560878 cites W2069810458 @default.
• W1596560878 cites W2098010219 @default.
• W1596560878 cites W2147607947 @default.
• W1596560878 cites W2151710788 @default.
• W1596560878 doi "https://doi.org/10.1186/s40360-015-0017-x" @default.
• W1596560878 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4475328" @default.
• W1596560878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26092545" @default.
• W1596560878 hasPublicationYear "2015" @default.
• W1596560878 type Work @default.
• W1596560878 sameAs 1596560878 @default.
• W1596560878 citedByCount "44" @default.
• W1596560878 countsByYear W15965608782016 @default.
• W1596560878 countsByYear W15965608782017 @default.
• W1596560878 countsByYear W15965608782018 @default.
• W1596560878 countsByYear W15965608782019 @default.
• W1596560878 countsByYear W15965608782020 @default.
• W1596560878 countsByYear W15965608782021 @default.
• W1596560878 countsByYear W15965608782022 @default.
• W1596560878 countsByYear W15965608782023 @default.
• W1596560878 crossrefType "journal-article" @default.
• W1596560878 hasAuthorship W1596560878A5006853195 @default.
• W1596560878 hasAuthorship W1596560878A5012242776 @default.
• W1596560878 hasAuthorship W1596560878A5021869798 @default.
• W1596560878 hasAuthorship W1596560878A5037747729 @default.
• W1596560878 hasAuthorship W1596560878A5041661080 @default.
• W1596560878 hasAuthorship W1596560878A5043635819 @default.
• W1596560878 hasAuthorship W1596560878A5046940384 @default.
• W1596560878 hasAuthorship W1596560878A5081663338 @default.
• W1596560878 hasAuthorship W1596560878A5091287615 @default.
• W1596560878 hasBestOaLocation W15965608781 @default.
• W1596560878 hasConcept C111113717 @default.
• W1596560878 hasConcept C112705442 @default.
• W1596560878 hasConcept C126322002 @default.
• W1596560878 hasConcept C12823836 @default.
• W1596560878 hasConcept C13373296 @default.
• W1596560878 hasConcept C142724271 @default.
• W1596560878 hasConcept C170493617 @default.
• W1596560878 hasConcept C197934379 @default.
• W1596560878 hasConcept C204787440 @default.
• W1596560878 hasConcept C22979827 @default.
• W1596560878 hasConcept C27081682 @default.
• W1596560878 hasConcept C71924100 @default.
• W1596560878 hasConcept C84913492 @default.
• W1596560878 hasConcept C98274493 @default.
• W1596560878 hasConceptScore W1596560878C111113717 @default.
• W1596560878 hasConceptScore W1596560878C112705442 @default.
• W1596560878 hasConceptScore W1596560878C126322002 @default.
• W1596560878 hasConceptScore W1596560878C12823836 @default.
• W1596560878 hasConceptScore W1596560878C13373296 @default.
• W1596560878 hasConceptScore W1596560878C142724271 @default.
• W1596560878 hasConceptScore W1596560878C170493617 @default.
• W1596560878 hasConceptScore W1596560878C197934379 @default.
• W1596560878 hasConceptScore W1596560878C204787440 @default.
• W1596560878 hasConceptScore W1596560878C22979827 @default.
• W1596560878 hasConceptScore W1596560878C27081682 @default.
• W1596560878 hasConceptScore W1596560878C71924100 @default.
• W1596560878 hasConceptScore W1596560878C84913492 @default.
• W1596560878 hasConceptScore W1596560878C98274493 @default.
• W1596560878 hasIssue "1" @default.
• W1596560878 hasLocation W15965608781 @default.
• W1596560878 hasLocation W15965608782 @default.
• W1596560878 hasLocation W15965608783 @default.
• W1596560878 hasLocation W15965608784 @default.
• W1596560878 hasOpenAccess W1596560878 @default.
• W1596560878 hasPrimaryLocation W15965608781 @default.
• W1596560878 hasRelatedWork W1541103017 @default.
• W1596560878 hasRelatedWork W1596560878 @default.
• W1596560878 hasRelatedWork W1752921906 @default.
• W1596560878 hasRelatedWork W1997101420 @default.
• W1596560878 hasRelatedWork W2158380752 @default.
• W1596560878 hasRelatedWork W2477866235 @default.
• W1596560878 hasRelatedWork W2617001846 @default.
• W1596560878 hasRelatedWork W3097307756 @default.
• W1596560878 hasRelatedWork W3205517375 @default.
• W1596560878 hasRelatedWork W3207379667 @default.
• W1596560878 hasVolume "16" @default.
• W1596560878 isParatext "false" @default.

• next